Global Pharma-Grade Nitric Oxide Market Size By Type (99.92% Purity,9999% Purity), By Application (Hospitals, Healthcare Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Pharma-Grade Nitric Oxide Market was valued at USD 0.72 billion in 2023 and is projected to reach USD 1.39 billion by 2031, expanding at a compound annual growth rate (CAGR) of 8.6% during the forecast period (2023–2031). This growth is primarily driven by the increasing use of nitric oxide in respiratory therapies, especially for treating conditions like persistent pulmonary hypertension of the newborn (PPHN), and acute respiratory distress syndrome (ARDS). The growing prevalence of chronic respiratory and cardiovascular conditions, coupled with advancements in drug delivery systems, is also significantly boosting market demand.

Drivers:

Rising Incidence of Respiratory Disorders:

The growing burden of respiratory diseases, particularly among neonates and the elderly, is a primary driver for the adoption of pharma-grade nitric oxide. Its effectiveness in improving oxygenation makes it essential in critical care settings.

Expanding Applications in Critical Care:

Beyond neonatal care, nitric oxide is increasingly used in adult critical care, especially in the management of ARDS and during heart surgeries, which expands its application base.

Technological Innovations in Delivery Devices:

Innovations in nitric oxide delivery systems, such as portable and digitally integrated units, are enhancing treatment precision and patient safety, thereby accelerating adoption in hospitals and clinics.

Restraints:

High Treatment Costs:

The use of nitric oxide therapy involves significant costs due to specialized delivery systems and monitoring equipment, limiting access in cost-sensitive regions.

Strict Regulatory Frameworks:

The production and administration of pharmaceutical-grade nitric oxide are subject to stringent regulatory standards, which may delay product approvals and market entry for new players.

Opportunity:

Growing Use in Cardiac and Pulmonary Surgeries:

The increasing number of cardiac surgeries and the use of nitric oxide to reduce complications present significant growth potential, particularly in developed healthcare markets.

Emerging Markets Expansion:

Rising healthcare investments in countries like India, China, and Brazil offer untapped opportunities for nitric oxide-based therapies, especially as access to neonatal intensive care units (NICUs) improves.

Market by System Type Insights:

Based on system type, the Standalone Delivery Systems segment led the market in 2023. These systems are highly favored in hospital settings for their ease of use, portability, and compatibility with intensive care equipment. However, the Integrated Delivery Systems segment is expected to witness the fastest growth, driven by increasing demand for streamlined patient monitoring and safety integration in high-acuity care environments.

Market by End-use Insights:

Hospitals emerged as the dominant end-use segment, accounting for over 60% of the total market revenue in 2023. This is attributed to the high demand for nitric oxide in neonatal and surgical units. Specialty clinics and ambulatory surgical centers are anticipated to grow steadily, supported by improvements in outpatient respiratory care services.

Market by Regional Insights:

North America held the largest market share in 2023 due to a robust healthcare infrastructure, early adoption of nitric oxide therapies, and favorable reimbursement policies. Meanwhile, the Asia-Pacific region is projected to grow at the highest CAGR, driven by rapid improvements in healthcare access, government initiatives for neonatal care, and rising awareness of respiratory conditions.

Competitive Scenario:

Key players in the Global Pharma-Grade Nitric Oxide Market include Mallinckrodt Pharmaceuticals, Linde plc, Praxair (now part of Linde), Air Liquide, Bellerophon Therapeutics, and Novoteris. These companies are actively engaged in expanding product lines, obtaining regulatory approvals, and forging partnerships to strengthen market positioning.

In 2024, Mallinckrodt received FDA clearance for an upgraded version of its INOmax DSIR® delivery system with enhanced digital monitoring capabilities.

In 2023, Bellerophon Therapeutics launched a pilot study on inhaled nitric oxide therapy in outpatient pulmonary fibrosis treatment.

Air Liquide expanded its nitric oxide production capabilities in Asia in 2022 to meet growing regional demand.

Scope of Work – Global Pharma-Grade Nitric Oxide Market

Report Metric Details

Market Size (2023) USD 0.72 billion

Projected Market Size (2031) USD 1.39 billion

CAGR (2023–2031) 8.6%

Market Segments By System Type (Standalone, Integrated), End-use (Hospitals, Clinics, ASCs)

Growth Drivers Rising respiratory disorders, innovations in delivery systems

Opportunities Expanding surgical applications, emerging markets

Key Market Developments:

2024: Mallinckrodt launches digitally upgraded nitric oxide delivery system for critical care units.

2023: Bellerophon initiates outpatient NO therapy trial for pulmonary fibrosis.

2022: Air Liquide expands nitric oxide production infrastructure in Southeast Asia.

FAQs:

1) What is the current market size of the Global Pharma-Grade Nitric Oxide Market?

The market was valued at USD 0.72 billion in 2023